On June 22, 2021 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, reported that the Company will be included in the Russell Microcap Index effective after the U.S. market opens on Monday, June 28, 2021, as based on the preliminary list of additions (Press release, Sellas Life Sciences, JUN 22, 2021, View Source [SID1234584232]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

"Inclusion in the Russell Microcap Index represents another important milestone for SELLAS and is an achievement that will undoubtedly increase awareness and visibility of our company within the investment community," said Angelos Stergiou, MD, ScD hc, President and Chief Executive Officer, SELLAS. "Our inclusion is a testament to our diligent work on our clinical development programs for our lead asset, galinpepimut-S (GPS) which have the potential to result in a treatment for multiple cancer indications that will help patients to stay in remission and live longer. We look forward to sharing the SELLAS story as well as updates on our execution and milestones, which are currently on track, with a wider investor audience as part of the FTSE Russell Microcap Index."

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective market-capitalization rankings and style attributes.

For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

About FTSE Russell:
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

On June 22, 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series – Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation – at 10:00 a.m. ET on Tuesday, June 29, 2021 (Press release, Regeneron, JUN 22, 2021, View Source [SID1234584231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the ‘Investors and Media’ page of Regeneron’s website at View Source A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.

On June 22, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that it has rescheduled the Company’s fireside chat being hosted by H.C. Wainwright, which was previously scheduled for today, to July 12, 2021 at 11 a.m. Eastern Time (Press release, Phio Pharmaceuticals, JUN 22, 2021, View Source [SID1234584230]). Details regarding the rescheduled fireside chat will be forthcoming.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Logo – View Source

On June 22, 2021 OPKO Health, Inc. (NASDAQ: OPK) reported the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO’s BioReference Laboratories (Press release, Opko Health, JUN 22, 2021, View Source [SID1234584229]). Ms. Stueland joins GeneDx from Invitae Corporation (NYSE: NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for diagnosing the most difficult human diseases," said Jon R. Cohen, MD, Executive Chairman of BioReference Laboratories. "With her depth of experience, focus on patient-centric business strategies and ability to lead and inspire, we look forward to a new era of genomics with GeneDx at the forefront."

Ms. Stueland’s career is rooted in bringing transformational technologies to patients and crafting strategies to enable broader access to diagnostics and therapeutics. She has overseen multiple commercial organizations and corporate brand transformations, and helped bring the first cancer immunotherapy to market, enabling a new standard of care for patients.

"The global opportunity is clear regarding the growing role of genomic information in providing better care to patients. We can readily and rapidly provide critical information to improve health outcomes, and GeneDx has been at the forefront of these efforts for more than 20 years," said Ms. Stueland, incoming President and CEO of GeneDx. "I’m honored to be joining this world-class team and couldn’t be more excited about what’s possible by bringing the GeneDx technologies to broader patient populations."

With more than two decades in the healthcare industry, Ms. Stueland previously held roles at Dendreon Corporation and TAP Pharmaceuticals (a joint venture of Takeda and Abbott), and consulted for biotech and pharmaceutical companies.

On June 22, 2021 Novo Nordisk reported that initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules") (Press release, Novo Nordisk, JUN 22, 2021, View Source [SID1234584228]). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the programme initiated 7 May 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.3 billion in the period from 10 May 2021 to 3 August 2021.

Since the announcement as of 14 June 2021, the following transactions have been made:

With the transactions stated above, Novo Nordisk owns a total of 14,210,192 B shares of DKK 0.20 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 18 billion during a 12- month period beginning 3 February 2021. As of 18 June 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 15,371,694 B shares at an average share price of DKK 459.84 per B share equal to a transaction value of DKK 7,068,566,393.